A Phase 3 Study of GSK5764227 in Participants with Relapsed Small Cell Lung Cancer (SCLC)
Résumé de l'étude
This study investigates the efficacy and safety of the drug GSK5764227 in participants with a relapse of small cell lung cancer (SCLC) compared to the approved standard medication Topotecan. GSK5764227 belongs to the class of antibody-drug conjugates (ADC). It is a specially designed antibody that recognizes the B7-H3 protein on the surface of cancer cells and can specifically destroy them. Participants whose SCLC has returned after initial platinum-based chemotherapy will be randomly assigned (in a 2:1 ratio) to two groups: - Experimental group: receives GSK5764227 (approximately 200 participants). The investigational drug is administered as an infusion every three weeks at a dosage of 8.0 mg/kg. - Control group: receives Topotecan (approximately 100 participants). Topotecan is administered intravenously for five consecutive days in a 21-day cycle. Both the participant and the investigator know which study drug is being administered (so-called open-label study). The study treatment will continue as long as it is deemed safe for the participant by the investigator, or until the disease worsens. Approximately 300 participants worldwide will be studied in this Phase 3 trial to gain new insights into the treatment of small cell lung cancer and to improve the currently limited therapies.
(BASEC)
Intervention étudiée
The investigational drug GSK5764227 belongs to the class of antibody-drug conjugates (ADC). An antibody is a protein that specifically recognizes certain molecules – here the B7-H3 protein, which is found on cancer cells but rarely in healthy tissue. The antibody binds to B7-H3 and releases a drug that attacks and kills the cancer cells.
(BASEC)
Maladie en cours d'investigation
Small Cell Lung Cancer (SCLC)
(BASEC)
1. The person must be at least 18 years old. 2. There must be a confirmed diagnosis of advanced small cell lung cancer (extensive stage small cell lung cancer, ES-SCLC). 3. The person must have received platinum-based chemotherapy consisting of at least 2 cycles and combined with immunotherapy (PD-(L)1 inhibitor), unless there were medical reasons against immunotherapy. At least 30 days must have passed between the last chemotherapy and the new treatment. 4. It must be documented that the cancer has continued to grow after the last treatment, and there must be at least one visible, measurable tumor site outside the brain. 5. The person has adequate organ function as required by laboratory tests. (BASEC)
Critères d'exclusion
1. Individuals with a diagnosis of complex small cell lung cancer (e.g., mixed small cell and non-small cell lung cancer) or transformed small cell lung cancer cannot participate. 2. Individuals with cancer that has spread to the brain (brain metastases) are excluded unless certain conditions are simultaneously met (discuss this with the investigator). All participants must undergo an MRI or CT scan of the brain before the study begins. 3. Individuals with an additional cancer diagnosis or a previous cancer diagnosis cannot participate, except for certain cancer types that have been completely and successfully treated (for at least 5 years). 4. Individuals who have had major surgery (such as brain, chest, or abdominal surgery) within the last 4 weeks before the first dose of the study are excluded. 5. Individuals who have already received another type of B7H3-targeted treatment. (BASEC)
Lieu de l’étude
Bâle, Lausanne
(BASEC)
Sponsor
GlaxoSmithKline AG
(BASEC)
Contact pour plus d'informations sur l'étude
Personne de contact en Suisse
Dr. Andreas Michael Schmitt
+41 61 265 50 74
andreasmichael.schmitt@clutterusb.chUniversitätsspital Basel Medzinische Onkologie
(BASEC)
Informations scientifiques
non disponible
Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)
Ethikkommission Nordwest- und Zentralschweiz EKNZ
(BASEC)
Date d'approbation du comité d'éthique
14.11.2025
(BASEC)
Identifiant de l'essai ICTRP
non disponible
Titre officiel (approuvé par le comité d'éthique)
Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in Participants with Relapsed Small Cell Lung Cancer (SCLC) (BASEC)
Titre académique
non disponible
Titre public
non disponible
Maladie en cours d'investigation
non disponible
Intervention étudiée
non disponible
Type d'essai
non disponible
Plan de l'étude
non disponible
Critères d'inclusion/exclusion
non disponible
non disponible
Critères d'évaluation principaux et secondaires
non disponible
non disponible
Date d'enregistrement
non disponible
Inclusion du premier participant
non disponible
Sponsors secondaires
non disponible
Contacts supplémentaires
non disponible
ID secondaires
non disponible
Résultats-Données individuelles des participants
non disponible
Informations complémentaires sur l'essai
non disponible
Résultats de l'essai
Résumé des résultats
non disponible
Lien vers les résultats dans le registre primaire
non disponible